296 related articles for article (PubMed ID: 34517739)
1. Lipid management across Europe in the real-world setting: a rapid evidence review.
Barrios V; Soronen J; Carter AM; Anastassopoulou A
Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
[TBL] [Abstract][Full Text] [Related]
2. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
3. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
4. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
5. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
6. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
[TBL] [Abstract][Full Text] [Related]
8. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
9. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
Shah NN; Ghazi L; Yamamoto Y; Kumar S; Martin M; Simonov M; Riello Iii RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010335. PubMed ID: 38634282
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
[TBL] [Abstract][Full Text] [Related]
11. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
12. Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.
Mackinnon ES; Har B; Champsi S; Wani RJ; Geyer L; Shaw E; Farris MS; Anderson TJ
Cardiol Ther; 2023 Jun; 12(2):327-338. PubMed ID: 36656500
[TBL] [Abstract][Full Text] [Related]
13. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
[TBL] [Abstract][Full Text] [Related]
14. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP
Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093
[TBL] [Abstract][Full Text] [Related]
15. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C
Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom DJ; Almahmeed W; Al-Rasadi K; Azuri J; Daclin V; Kayikcioglu M; Mercier F; Ruiz AJ; Santos RD;
J Clin Lipidol; 2019; 13(4):594-600. PubMed ID: 31208705
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
[TBL] [Abstract][Full Text] [Related]
18. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
19. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
[TBL] [Abstract][Full Text] [Related]
20. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
